Strategic Cost Reduction
Ensure your program's long-term commercial viability by preventing expensive late-stage redesigns, optimizing capital allocation, and avoiding unsustainable royalty burdens
Technical Know-How: Avoiding High Licensing Costs
The IP landscape for mRNA and DNA is dense; we integrate IP strategy into CMC development to avoid unsustainable royalty burdens.
Strategic "Design-Arounds"
Identifying technically viable alternatives for sequence modifications, modified nucleotide chemistry, E. coli or host strain that achieve performance goals while avoiding existing patent claims.
Technology Access Alternatives
Evaluating whether in-licensing is the optimal path or if alternative strategies—such as opposition proceedings or alternative technologies—offer a more favorable risk-benefit profile.
COGS Modeling
Disaggregating total manufacturing costs into labor, raw materials, equipment, quality/analytical testing, overhead to identify high-leverage optimization opportunities.
Process-Level Savings
Optimizing reaction yield to reduce raw material consumption, reduce impurity formation, refining enzyme loading, and extending chromatography resin lifetimes.
Infrastructure Optimization
Performing Build versus Buy analyses to determine the cost and risk implications of internal manufacturing versus CDMO reliance.
Let us help maximize your impact.
Smart molecule design is critical for execution!
Our strategy is built for robustness, success and speed. The correct design strategy saves time and decreases wet lab experiment design space, enables faster synthesis and scale up optimization to accelerate development freeing up your resources. Reduction of royalty and licensing costs and avoid common pitfalls. Reduced COGs and longer-term strategy baked in to ensure compliance with regulatory requirements.
Frequently Asked Questions
How do you identify and address early manufacturing cost drivers?
We rely on comprehensive Cost of Goods (COGS) modeling to disaggregate your total manufacturing costs into specific categories, such as labor, raw materials, equipment, analytical testing, and overhead. This quantitative approach allows us to pinpoint high-leverage optimization opportunities early in development to ensure commercial viability.
How can we navigate the dense intellectual property landscape without facing crippling licensing costs?
We directly integrate IP strategy into your CMC development to help you avoid unsustainable royalty burdens. A key part of this is developing strategic "design-arounds"—identifying technically viable alternatives for sequence modifications, nucleotide chemistry, or E. coli host strains that achieve your performance goals while safely avoiding existing patent claims.
What if in-licensing a specific technology seems too restrictive or expensive?
We evaluate Technology Access Alternatives to determine if in-licensing is truly the optimal path for your program. If it is not, we assess whether other strategies—such as opposition proceedings or utilizing alternative technologies—offer a more favorable risk-benefit profile.
What specific process-level changes do you implement to save money?
At the process level, we focus on optimizing reaction yields to decrease raw material consumption and reduce impurity formation. We also drive significant savings by refining enzyme loading and implementing strategies to extend the lifetimes of chromatography resins.
Can you help us decide whether to build our own manufacturing facility or use a CDMO?
Yes, we perform comprehensive "Build versus Buy" analyses. This infrastructure optimization exercise thoroughly evaluates the cost and risk implications of internal manufacturing versus relying on a CDMO, allowing you to make the most strategic long-term decision.